Quality of life of patients with thyroid eye disease: 3-year follow-up in a multidisciplinary clinic in Israel.
European Group on Graves’ Orbitopathy
Graves’ orbitopathy
Quality of life
Thyroid eye disease
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
06
11
2020
accepted:
25
01
2021
revised:
25
12
2020
pubmed:
3
2
2021
medline:
19
8
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
Changes in the quality of life (QOL) of patients with thyroid eye disease (TED) were examined during a 3-year follow-up in a multidisciplinary eye clinic, and factors that may improve QOL were identified. A retrospective review of medical records of all patients who attended the TED clinic at Sheba Medical Center, Israel, from May 2016 to May 2019 was performed. The retrieved data included demographics, comprehensive ophthalmic examination findings, clinical activity scores (CAS), laboratory test results, and QOL assessments by the Graves' Orbitopathy QOL (GO-QOL) questionnaire. One hundred thirty-two TED clinic patients were examined. Thirty patients (22.72%) received medical treatment consisting of steroids according to the European Group on Graves' Orbitopathy (EUGOGO) protocol, high-dose steroids, or immunosuppressive drugs. Twenty-eight patients (21.21%) underwent surgical rehabilitation (decompression, strabismus, or eyelid surgery). There was a significant increase in total QOL score after steroid treatment according to the EUGOGO protocol, after decompression surgery, and after strabismus surgery compared to pre-treatment total QOL (p=0.04, p=0.021, and p=0.042, respectively, matched pairs). In addition, there were significant positive correlations between the changes in the total QOL score and the change in thyroid-stimulating immunoglobulin (TSI) as well as the change in CAS among the patients who underwent medical and surgical interventions. QOL improved significantly after medical/surgical treatments. A change in the CAS and in the TSI may also correlate with change in QOL. Periodic evaluation of TED patients' QOL is recommended for enhanced and more comprehensive management.
Sections du résumé
BACKGROUND
BACKGROUND
Changes in the quality of life (QOL) of patients with thyroid eye disease (TED) were examined during a 3-year follow-up in a multidisciplinary eye clinic, and factors that may improve QOL were identified.
METHODS
METHODS
A retrospective review of medical records of all patients who attended the TED clinic at Sheba Medical Center, Israel, from May 2016 to May 2019 was performed. The retrieved data included demographics, comprehensive ophthalmic examination findings, clinical activity scores (CAS), laboratory test results, and QOL assessments by the Graves' Orbitopathy QOL (GO-QOL) questionnaire.
RESULTS
RESULTS
One hundred thirty-two TED clinic patients were examined. Thirty patients (22.72%) received medical treatment consisting of steroids according to the European Group on Graves' Orbitopathy (EUGOGO) protocol, high-dose steroids, or immunosuppressive drugs. Twenty-eight patients (21.21%) underwent surgical rehabilitation (decompression, strabismus, or eyelid surgery). There was a significant increase in total QOL score after steroid treatment according to the EUGOGO protocol, after decompression surgery, and after strabismus surgery compared to pre-treatment total QOL (p=0.04, p=0.021, and p=0.042, respectively, matched pairs). In addition, there were significant positive correlations between the changes in the total QOL score and the change in thyroid-stimulating immunoglobulin (TSI) as well as the change in CAS among the patients who underwent medical and surgical interventions.
CONCLUSIONS
CONCLUSIONS
QOL improved significantly after medical/surgical treatments. A change in the CAS and in the TSI may also correlate with change in QOL. Periodic evaluation of TED patients' QOL is recommended for enhanced and more comprehensive management.
Identifiants
pubmed: 33528651
doi: 10.1007/s00417-021-05103-5
pii: 10.1007/s00417-021-05103-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2009-2015Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Références
Bahn RS (2010) Graves’ ophthalmopathy. N Engl J Med 362(8):726–738
doi: 10.1056/NEJMra0905750
Bahmani-Kashkouli M, Pakdel F, Astaraki A et al (2009) Quality of life in patients with thyroid eye disease. J Ophthalmic Vis Res 4:164–168
pubmed: 23198067
pmcid: 3498563
Gerding MN, Terwee CB, Dekker FW et al (1997) Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid 7:885–889
doi: 10.1089/thy.1997.7.885
Estcourt S, Quinn AG, Vaidya B (2011) Quality of life in thyroid eye disease: impact of quality of care. Eur J Endocrinol 164:649–655
doi: 10.1530/EJE-11-0055
Wiersinga WM, Prummel MF, Terwee CB (2004) Effects of Graves’ ophthalmopathy on quality of life. J Endocrinol Investig 27:259–264
doi: 10.1007/BF03345275
Bradley EA, Sloan JA, Novotny PJ et al (2006) Evaluation of the National Eye Institute visual function questionnaire in Graves’ ophthalmopathy. Ophthalmology 113(8):1450–1454
doi: 10.1016/j.ophtha.2006.02.060
Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol 47:9–14
doi: 10.1046/j.1365-2265.1997.2331047.x
Bartalena L, Baldeschi L, Dickinson A et al (2008) Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273–285
doi: 10.1530/EJE-07-0666
Bartalena L, Baldeschi L, Boboridis K et al (2016) The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of graves’ orbitopathy. Eur Thyroid J 5:9–26
doi: 10.1159/000443828
Iacobæus L, Sahlin S (2016) Evaluation of quality of life in patients with Graves’ ophthalmopathy, before and after orbital decompression. Orbit 35:121–125
doi: 10.1080/01676830.2016.1176049
Jellema HM, Merckel-Timmer E, Kloos R et al (2014) Quality of life improves after strabismus surgery in patients with Graves’ orbitopathy. Eur J Endocrinol 170:785–789
doi: 10.1530/EJE-13-0973
Jellema HM, Saeed P, Mombaerts I et al (2017) Objective and subjective outcomes of strabismus surgery in Graves’ orbitopathy: a prospective multicentre study. Acta Ophthalmol 95:386–391
doi: 10.1111/aos.13367
Kashkouli M, Heidari I, Pakdel F et al (2011) Change in quality of life after medical and surgical treatment of Graves’ ophthalmopathy. Middle East Afr J Ophthalmol 18:42
doi: 10.4103/0974-9233.75884
Wickwar S, McBain H, Ezra DG et al (2015) The psychosocial and clinical outcomes of orbital decompression surgery for thyroid eye disease and predictors of change in quality of life. Ophthalmology 122:2568–76.e1
doi: 10.1016/j.ophtha.2015.08.030
Verity DH, Rose GE (2013) Acute thyroid eye disease (TED): principles of medical and surgical management. Eye (Lond) 27(3):308–19
doi: 10.1038/eye.2012.284
Vogel A, Elberling TV, Hørding M et al (2007) Affective symptoms and cognitive functions in the acute phase of Graves’ thyrotoxicosis. Psychoneuroendocrinology 32:36–43
doi: 10.1016/j.psyneuen.2006.09.012
Ponto KA, Kanitz M, Olivo PD et al (2011) Clinical relevance of thyroid-stimulating immunoglobulins in Graves’ ophthalmopathy. Ophthalmology 118:2279–2285
doi: 10.1016/j.ophtha.2011.03.030
Lytton SD, Li Y, Olivo PD et al (2010) Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol 162:438–446
doi: 10.1111/j.1365-2249.2010.04266.x